Consumer Reports Negative on Teva Pharma (TEVA), Mylan (MYL) Deal

Consumer Reports is out negative on the potential deal between Mylan (Nasdaq: MYL) and Teva Pharma (NYSE: TEVA).

In part, the report notes that the deal could hand consumers higher prices for generic and specialty drugs.

Teva and Mylan are both trading at or near session lows on Friday.

You May Also Be Interested In

• Chime Financial (CHYM) PT Raised to $42 at Compass Point
• Regency Silver to acquire Jabali gold project in Sonora, Mexico
• GameSquare to acquire FanEngine assets in ~$15.9M stock deal